The effects of L-Dopa and N-(alpha-linolenoyl) tyrosine on 6-OH-DA lesions on dopamine level and activity, dyskinesia and homocysteinemia in rats

Shlomo Yehuda, Sharon Rabinovitz-Shenkar

Department of Criminology, Bar Ilan University, Ramat Gan, Israe.
Department of Psychology, Bar Ilan University, Ramat Gan, Israel.

DOI: 10.4236/apd.2013.21001                

Abstract

The three major issues in L-DOPA therapy for Parkinson are: 1) rapid tolerance; 2) induced dyskinesia; 3) hyperhomocysteinemia. The newly synthesized molecule, which is an amide bond molecule composed of L-tyrosine and alphalinolenic acid, i.e., N-(alpha-linolenoyl) tyrosine (NLT), represents a new class of molecules that combines essential amino acids with essential fatty acids. This study demonstrates that acute administration of NLT results in prolonged increase of the brain dopamine level, and that this molecule is able to overcome the three major problems associated with Parkinson’s L-DOPA therapy: it is able to elevate brain dopamine levels and increase activity, without inducing tolerance, dyskinesia or hyperhomocysteinemia.

Keywords

Parkinson; Dopamine; Tolerance; Dyskinesia; Homocysteine; Rotational Behavior

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Nutt, J.G., Obeso, J.A. and Stocchi F. (2000) Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends in Neurosciences, 10, S109-S15. doi:10.1016/S1471-1931(00)00029-X
[2]	Troen, A. and Rosenberg, I. (2005). Homocysteine and cognitive function. Seminars in Vascular Medicine, 2, 209-214. doi:10.1055/s-2005-872406
[3]	Yehuda, S., Rabinovitz, S. and Mostofsky, D.I. (2005) Essential fatty acids and the brain: from infancy to aging. Neurobiology of Aging, 26, 98-102. doi:10.1016/j.neurobiolaging.2005.09.013
[4]	Yehuda, S. (2002) Possible anti-Parkinson properties of N-(alpha-linolenoyl) tyrosine: a new molecule. Pharmacology, Biochemistry and Behavior, 72, 7-11. doi:10.1016/S0091-3057(01)00646-3
[5]	Samadi, P., Gregiore, L., Rouillard, C., Bedard, P.J., Di Paolo, T. and Levesque, D. (2006) Docosahexaenoic acid reduces levadopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Annals of Neurology, 59, 282-288. doi:10.1002/ana.20738
[6]	De Bree, A., Mennen, L.I., Hercberg, S. and Galan, P. (2004) Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition, 58, 732-744. doi:10.1038/sj.ejcn.1601871
[7]	Konig, J.F.R. and Klippel, R.A. (1963) The rat brain: a stereotaxic atlas of the forebrain and lower parts of the brain stem. Williams and Wilkins, Baltimore.
[8]	Dekundy, A., Lundblad, M., Danysz, W. and Cenci, M.A. (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behavioural Brain Research, 179, 76-89. doi:10.1016/j.bbr.2007.01.013
[9]	Araki, A. and Sako, Y. (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography, 422, 43-52.
[10]	Zesiewicz, T.A., Wecker, L., Sullivan, K.L., Merlin, L.R. and Hauser, R.A. (2006) Topiramate-induced psychosis in patients with essential tremor: Report of 2 cases. Clinical Neuropharmacology, 29, 106-111. doi:10.1097/01.WNF.0000220817.94102.95
[11]	Kim, J.M., Lee, H. and Chang, N. (2002) Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain. Journal of Nutrition, 132, 3418-3421.